Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption.
In the present study, the pharmacokinetics of extractive GAGs used as therapeutic agents have been studied after intravenous and oral administration on volunteers. The use of native or deuterium-labeled compounds, followed by HPLC/MS detection, allowed the quantitation of exogenous heparin and DS as major disaccharide fragments, obtained either by enzymatic or chemical depolymerization. In particular the high level of labeling reached in DS allowed its differentiation from structurally related endogenous species. The estimated plasmatic bioavailability was about 18% for DS. Notwithstanding the impossibility of evaluating the same parameters for heparin species, due to the interferences of endogenous GAGs, the results obtained provided clear evidence of oral availability of heparin and DS through detection and quantitation of structures specifically related to these GAGs. Due to the selectivity of the lyases used, the enzymatic degradation specifically allowed the detection of both DS and heparin species still retaining the original sulfation pattern. Additionally, the chemical degradation could detect the main metabolites of the drugs, consisting of partially to totally desulfated GAGs showing a more or less marked reduction in their molecular weight.
Silvestro
L
L
Res Pharma Pharmacological Research Srl, Torino, Italy.
Lanzarotti
E
E
Marchi
E
E
Gori
M
M
Pescador
R
R
Ferro
L
L
Milani
M R
MR
Da Col
R
R
Coppini
A
A
D000284:Administration, Oral; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D003871:Dermatan Sulfate / Q000097:blood*; D003903:Deuterium; D006025:Glycosaminoglycans / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D007408:Intestinal Absorption / Q000502:physiology*; D013058:Mass Spectrometry; D012016:Reference Values
D006025:Glycosaminoglycans; D003871:Dermatan Sulfate; D003903:Deuterium